Eliquis Regulatory Post Marketing Surveillance | NCT01885598 | Trialant

Eliquis Regulatory Post Marketing Surveillance | NCT01885598 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Nonvalvular Atrial Fibrillation patients with risk of Stroke		Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release	Drug: Apixaban

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Adverse events (AE) occurrence based on Incidence of serious adverse events, unexpected adverse drug reactions, Identification of AE profile in usual practice Nonserious adverse events, major bleeding		within 30 days after end of the treatment

Secondary Outcomes

Measure	Description	Time Frame
Final identification of major events and no event based on Incidence of stroke, systemic embolism, death, Effectiveness or death at 24 months after discontinuation of therapy or at the end of the observation period (whatever is later)	Final identification of major events based on Incidence of stroke, systemic embolism, death, Effectiveness: No evidence of stroke, systemic embolism, or death at 24 months after discontinuation of therapy or at the end of the observation period (whatever is later)

Contacts/Locations Module

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
35135065	Derived	Kim JS, Koo J, Shin DI, Kim BS, Kim J, Kim EG, Hong KS, Yi H. Apixaban for Secondary Stroke Prevention: Coexistant Cerebral Atherosclerosis May Increase Recurrent Strokes. J Stroke. 2022 Jan;24(1):118-127. doi: 10.5853/jos.2021.02355. Epub 2022 Jan 31.